share_log

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga ·  Mar 15 21:06

Gainers

  • Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million.
  • Madrigal Pharmaceuticals (NASDAQ:MDGL) shares moved upwards by 22.34% to $298.0. The market value of their outstanding shares is at $5.9 billion.
  • Akebia Therapeutics (NASDAQ:AKBA) stock rose 16.05% to $1.59. The market value of their outstanding shares is at $299.5 million. As per the press release, Q4 earnings came out yesterday.
  • Rallybio (NASDAQ:RLYB) shares increased by 15.98% to $1.85. The company's market cap stands at $69.9 million. The company's, Q4 earnings came out 3 days ago.
  • Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 15.6% to $5.78. The market value of their outstanding shares is at $4.6 million.
  • Vivos Therapeutics (NASDAQ:VVOS) stock rose 15.02% to $4.9. The market value of their outstanding shares is at $6.5 million.

Losers

  • SELLAS Life Sciences Gr (NASDAQ:SLS) stock decreased by 33.5% to $1.03 during Friday's pre-market session. The company's market cap stands at $44.7 million.
  • Lucy Scientific Discovery (NASDAQ:LSDI) shares fell 25.53% to $1.24. The market value of their outstanding shares is at $2.1 million.
  • Graphite Bio (NASDAQ:GRPH) shares decreased by 15.23% to $2.95. The company's market cap stands at $171.7 million.
  • Psyence Biomedical (NASDAQ:PBM) stock decreased by 10.06% to $1.43. The market value of their outstanding shares is at $19.1 million.
  • Geron (NASDAQ:GERN) stock declined by 9.41% to $3.07. The market value of their outstanding shares is at $1.6 billion.
  • First Wave BioPharma (NASDAQ:FWBI) stock fell 7.27% to $4.98. The market value of their outstanding shares is at $7.7 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment